

AUG 29 2006

Express Mail No.: EV 869858299 US
Date of Deposit: August 29, 2006Page 1 of 2
Attorney Docket No.: 26505-525 NATL

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/566,149
		Filing Date	January 27, 2006
		First Named Inventor	Oyelere
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	26505-525 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	EP 0 352 781 A2	E.I. DU PONT DE NEMOURS AND COMPANY	01/31/90	
	B2	EP 0 694 543 A1	BAYER AG	01/31/96	NO
	B3	WO 93/09103	THE UP-JOHN COPMANY	05/13/93	
	B4	WO 98/54161	PHARMACIA & UPJOHN COMPANY	12/03/98	
	B5	WO 99/33839	CHEIL JEDANG CORPORATION	07/08/99	
	B6	WO 00/10566	BRISTOL-MYERS SQUIBB COMPANY	03/02/00	
	B7	WO 00/29396	BAYER AKTIENGESELLSCHAFT	05/25/00	Abstract only
	B8	WO 01/32633	F. HOFFMANN-LA ROCHE AG	05/10/01	Abstract only
	B9	WO 01/42229 A1	ORTHO-MCNEIL PHARMACEUTICAL, INC.	06/14/01	
	B10	WO 01/81350 A1	ASTRAZENECA UK LIMITED	11/01/01	
	B11	WO 01/94342 A1	DONG A PHARM. CO., LTD.	12/13/01	
	B12	WO 03/084534 A1	PHARMACIA & UPJOHN COMPANY	10/16/03	
	B13	WO 2004/056819 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
	B14	WO 2005/012271 A2	RIB-X PHARMACEUTICALS, INC.	02/10/05	
	B15	WO 2005/019211 A2	RIB-X PHARMACEUTICALS, INC.	03/03/05	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

Express Mail No.: EV 869858299 US
 Date of Deposit: August 29, 2006

Page 2 of 2
 Attorney Docket No.: 26505-525 NATL

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Brickner, S.J., <i>urrent Pharmaceutical Design</i> , 2:175-194 (1996)
	C2	Zurenko et al. <i>Exp. Opin. Invest. Drugs</i> , 6(6):151-158 (1997)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Sun Jae Loewe/	Date Considered	05/08/2008
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2192098v.1